A PYMNTS Company

Canada: Pharmaceutical divestment forces conglomerate to revise financial outlook

By  |  March 31, 2013
Canada: Pharmaceutical divestment forces conglomerate to revise financial outlook

A major Canadian conglomerate has announced its plans to divest its pharmaceutical company and sell the business to Kohl & Frisch Limited for between $80 million and $100 million. AmerisourceBergen Corporation will divest AmerisourceBergen Canada Corporation to the fulltime distributor in a deal that the parties expect to finalize in the year’s third fiscal quarter. ABCC represented about 2 percent of AmerisourceBergen’s total revenues; due to the transaction the company will reportedly revise its planned financial performance expectations.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

     

    Full Content: Fort Mill Times

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.